Cargando…
EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features
BACKGROUND: Enhancer of zest homolog 2 (EZH2), a histone 3 methyltransferase, is associated with aggressive behavior of many tumors and is a promising target of molecular therapy. METHODS: To better elucidate the relevance of EZH2 in breast cancer subtypes, we evaluated EZH2 expression in 226 invasi...
Autores principales: | Guo, Shuangping, Li, Xia, Rohr, Joseph, Wang, Yingmei, Ma, Shirong, Chen, Peng, Wang, Zhe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845361/ https://www.ncbi.nlm.nih.gov/pubmed/27113214 http://dx.doi.org/10.1186/s13000-016-0491-5 |
Ejemplares similares
-
Impact of EZH2 Polymorphisms on Urothelial Cell Carcinoma Susceptibility and Clinicopathologic Features
por: Yu, Yung-Luen, et al.
Publicado: (2014) -
MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases
por: Ma, Shirong, et al.
Publicado: (2018) -
Role of Immunophenotypes in Carcinoma Breast
por: Shukla, Samarth, et al.
Publicado: (2018) -
Ceruminous Gland Carcinomas: A Clinicopathologic and Immunophenotypic Study of 17 Cases
por: Crain, Nikhil, et al.
Publicado: (2008) -
Hodgkin lymphoma: A clinicopathological and immunophenotypic study
por: Konkay, Kaumudi, et al.
Publicado: (2016)